Circulating tumour cell gene expression and chemosensitivity analyses: predictive accuracy for response to multidisciplinary treatment of patients with unresectable refractory recurrent rectal cancer or unresectable refractory colorectal cancer liver metastases

[1]  S. Sebens,et al.  Isolation and Enumeration of CTC in Colorectal Cancer Patients: Introduction of a Novel Cell Imaging Approach and Comparison to Cellular and Molecular Detection Techniques , 2020, Cancers.

[2]  F. Basile,et al.  The Liquid Biopsy in the Management of Colorectal Cancer: An Overview , 2020, Biomedicines.

[3]  F. Masedu,et al.  A Pilot Study of the Predictive Potential of Chemosensitivity and Gene Expression Assays Using Circulating Tumour Cells from Patients with Recurrent Ovarian Cancer , 2020, International journal of molecular sciences.

[4]  L. Cappabianca,et al.  Hypoxia-induced alternative splicing: the 11th Hallmark of Cancer , 2020, Journal of experimental & clinical cancer research : CR.

[5]  J. Mielgo-Ayuso,et al.  Liquid Biopsy as Novel Tool in Precision Medicine: Origins, Properties, Identification and Clinical Perspective of Cancer’s Biomarkers , 2020, Diagnostics.

[6]  F. Masedu,et al.  Circulating tumour cell liquid biopsy in selecting therapy for recurrent cutaneous melanoma with locoregional pelvic metastases: a pilot study , 2020, BMC Research Notes.

[7]  L. Ding,et al.  Perspectives of the Application of Liquid Biopsy in Colorectal Cancer , 2020, BioMed research international.

[8]  M. Valenti,et al.  Real-life multidisciplinary treatment for unresectable colorectal cancer liver metastases including hepatic artery infusion with chemo-filtration and liquid biopsy precision oncotherapy: observational cohort study , 2020, Journal of Cancer Research and Clinical Oncology.

[9]  P. Levkin,et al.  Precision Medicine in Oncology: In Vitro Drug Sensitivity and Resistance Test (DSRT) for Selection of Personalized Anticancer Therapy , 2020, Advanced Therapeutics.

[10]  F. Masedu,et al.  Precision oncotherapy based on liquid biopsies in multidisciplinary treatment of unresectable recurrent rectal cancer: a retrospective cohort study , 2019, Journal of Cancer Research and Clinical Oncology.

[11]  V. Arrazubi,et al.  Circulating Tumor Cells in Patients Undergoing Resection of Colorectal Cancer Liver Metastases. Clinical Utility for Long-Term Outcome: A Prospective Trial , 2019, Annals of Surgical Oncology.

[12]  A. Iliopoulos,et al.  Gene expression profiling as a potential predictor between normal and cancer samples in gastrointestinal carcinoma , 2019, Oncotarget.

[13]  Yangchao Chen,et al.  Clinical significance of exosomes as potential biomarkers in cancer , 2019, World journal of clinical cases.

[14]  Xiaohua Hu,et al.  Circulating tumor cells as an independent prognostic factor in advanced colorectal cancer: a retrospective study in 121 patients , 2019, International Journal of Colorectal Disease.

[15]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[16]  E. Ricevuto,et al.  KRAS, NRAS and BRAF mutations detected by next generation sequencing, and differential clinical outcome in metastatic colorectal cancer (MCRC) patients treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy , 2018, Oncotarget.

[17]  I. Papasotiriou,et al.  Evaluation of a simple method for storage of blood samples that enables isolation of circulating tumor cells 96 h after sample collection , 2017, Journal of Biological Research-Thessaloniki.

[18]  F. Masedu,et al.  Mitomycin C hypoxic pelvic perfusion for unresectable recurrent rectal cancer: pharmacokinetic comparison of surgical and percutaneous techniques , 2017, Updates in Surgery.

[19]  G. Fiorentini,et al.  Chemoembolization Adopting Polyethylene Glycol Drug-Eluting Embolics Loaded With Doxorubicin for the Treatment of Hepatocellular Carcinoma. , 2017, AJR. American journal of roentgenology.

[20]  Robyn L. Temple-Smolkin,et al.  Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Robyn L. Temple-Smolkin,et al.  Molecular Biomarkers for the Evaluation of Colorectal Cancer , 2017, American journal of clinical pathology.

[22]  K. Blom,et al.  Predictive Value of Ex Vivo Chemosensitivity Assays for Individualized Cancer Chemotherapy: A Meta-Analysis , 2017, SLAS technology.

[23]  R. Rosell,et al.  Real-time liquid biopsies become a reality in cancer treatment. , 2015, Annals of translational medicine.

[24]  M. Daidone,et al.  Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS‐BRAF wild‐type colorectal cancer receiving cetuximab or panitumumab , 2015, International journal of cancer.

[25]  I. Vlachou,et al.  Detection of Circulating Tumor Cells in Patients with Breast, Prostate, Pancreatic, Colon and Melanoma Cancer: A Blinded Comparative Study Using Healthy Donors , 2015 .

[26]  E. Ricevuto,et al.  The prevalent KRAS exon 2 c.35 G>A mutation in metastatic colorectal cancer patients: A biomarker of worse prognosis and potential benefit of bevacizumab-containing intensive regimens? , 2015, Critical reviews in oncology/hematology.

[27]  J. Wenner,et al.  Cytokeratin 20 improves the detection of circulating tumor cells in patients with colorectal cancer. , 2015, Cancer letters.

[28]  Y. Yoon,et al.  Recent applications of chemosensitivity tests for colorectal cancer treatment. , 2014, World journal of gastroenterology.

[29]  S. Manta,et al.  Comparison of the growth curves of cancer cells and cancer stem cells. , 2014, Current stem cell research & therapy.

[30]  E. Ricevuto,et al.  Worse prognosis of KRAS c.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) , 2013, BMC Medicine.

[31]  F. Giuliante,et al.  Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab. , 2012, Clinical colorectal cancer.

[32]  L. McShane.  Statistical challenges in the development and evaluation of marker-based clinical tests , 2012, BMC Medicine.

[33]  E. Ricevuto,et al.  Intensive chemotherapy of metastatic colorectal cancer: weighing between safety and clinical efficacy , 2011, Expert opinion on biological therapy.

[34]  E. Ricevuto,et al.  "Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study , 2010, BMC Cancer.

[35]  S. Iacobelli,et al.  Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: a dose-finding and phase II study. , 2010, Oncology reports.

[36]  F. Sarkar,et al.  Elimination of Colon Cancer Stem-Like Cells by the Combination of Curcumin and FOLFOX. , 2009, Translational oncology.

[37]  Andrea Mambrini,et al.  Prognostic Factors in Patients With Advanced Pancreatic Adenocarcinoma Treated With Intra-Arterial Chemotherapy , 2008, Pancreas.

[38]  B. Vainer,et al.  Prognostic significance of numeric aberrations of genes for thymidylate synthase, thymidine phosphorylase and dihydrofolate reductase in colorectal cancer , 2008, Acta oncologica.

[39]  Daniel J Sargent,et al.  Clinical trial designs for predictive marker validation in cancer treatment trials. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  E. Chu,et al.  The Role of Thymidylate Synthase as a Molecular Biomarker , 2004, Clinical Cancer Research.

[41]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[42]  B. Naume,et al.  Circulating tumor cells in patients with colorectal liver metastasis predict impaired survival. , 2015, Annals of surgery.

[43]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[44]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[45]  B. Teicher,et al.  Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. , 1981, Cancer research.

[46]  Thomas D. Schmittgen,et al.  Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2 2 DD C T Method , 2022 .